At its Meeting on 30 May 2022, the Transparency Council adopted Position No. 53/2022 on the legitimacy of granting approval for the reimbursement of the foodstuff for particular nutritional uses Betaquik in the following indications: GLUT-1 glucose transporter deficiency, drug-resistant epilepsy.